Mometasone Furoate Market Size & Share by Dosage Form (Nasal Spray, Cream, Ointment, Inhalers); Indication (Inflammatory Skin Disorders, Asthma, Allergic Rhinitis); Route of Administration (Nasal, Topical, Oral); Distribution Channel (Hospital, Retail, Online) - Global Supply & Demand Analysis, Growth Forecasts, Statistics Report 2024-2036

  • Report ID: 5507
  • Published Date: Jan 05, 2024
  • Report Format: PDF, PPT

Companies Dominating the Mometasone Furoate Landscape

    • Perrigo Company plc
      • Company Overview
      • Business Strategy
      • Key Product Offerings
      • Financial Performance
      • Key Performance Indicators
      • Risk Analysis
      • Recent Development
      • Regional Presence
      • SWOT Analysis
    • Bausch Health Companies Inc.
    • Glenmark Pharmaceuticals Limited
    • Vetoquinol USA
    • AstraZeneca plc
    • Intersect ENT

Browse Key Market Insights with Data Illustration:


In The News

  • May 2021 - The world-renowned, research-driven pharmaceutical business Glenmark Pharmaceuticals Limited has announced the introduction of Ryaltris®-AZ Nasal Spray in India for the management of moderate to severe allergic rhinitis. As a market leader in the respiratory industry, Glenmark was the first in India to introduce a branded generic version for the treatment of allergic rhinitis at a reasonable price. Patients will now have access to a considerably more practical and affordable therapy alternative across the nation.
  • Sepetember 2022 - Simplera® (florfenicol, terbinafine, mometasone furoate) Otic Solution for Dogs is now available, according to Vetoquinol USA. It is the least expensive single-dose treatment for canine otitis externa linked to sensitive strains of bacteria (Staphylococcus pseudintermedius) and yeast (Malassezia pachydermatis). The first and only bioequivalent generic for Claro® (florfenicol, terbinafine, mometasone furoate) Otic Solution is called Simplera, and it has FDA approval.

Author Credits:  Smruti Ranjan, Rajrani Baghel

  • Report ID: 5507
  • Published Date: Jan 05, 2024
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

Increasing research & development activities, rising product launches, and growing cases of respiratory allergies are the major factors driving the growth of the mometasone furoate market.

The market size of mometasone furoate is anticipated to attain a CAGR of 7% over the forecast period, i.e., 2024 – 2036.

The major players in the market are Perrigo Company plc, Bausch Health Companies Inc., Glenmark Pharmaceuticals Limited, Vetoquinol USA, AstraZeneca plc, Intersect ENT, Kyorin Remedio Co., Ltd, Teikoku Seiyaku Co., Ltd., Mitsubishi Tanabe Pharma Corporation, Takeda Pharmaceuticals, and others.

The allergic rhinitis segment is anticipated to garner the largest market size by the end of 2036 and display significant growth opportunities.

The market in the North America region is projected to hold the largest market share by the end of 2036 and provide more business opportunities in the future.
Inquiry Before Buying Request Free Sample

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying